Simon Baker

In some markets, that's up to 2% of the population. So I just wonder if you could give us an idea on your thoughts of the size of that opportunity

You alluded to the fact that it is under evaluation in non small cell lung cancer

I just wonder if you could give us some of your feedback on the patient and physician experience and reaction to Yeztugo

when you are expecting to see a potential benefit, as the lower cost of patients increases starts and increases stay time

should we assume that the entirety is SPIKE vax? And also, Jamie, I wonder if you could give us any comments on phasing

You mentioned the spend on respiratory trials being 50%. Was that 50% of your total trial spend or 50% of your R&D spend

I just wonder what the scope of your ambition was in that setting, given the role of T cell infiltration in glaucoma